ImmuneCyte Inc. is a global biopharmaceutical company based in Irvine, California, specializing in the research and development of innovative cell and gene therapeutics. Their focus is on developing best-in-class cell therapies to combat cancer, vascular, orthopedic, and aging-related diseases. With access to state-of-the-art laboratory facilities in Tianjin, China, ImmuneCyte leverages their proprietary CARTXpress platform to develop a robust pipeline of cell and gene therapy products for the treatment of various cancers and rare genetic disorders.
Utilizing their high-efficient and versatile cellular processing and manufacturing platform, ImmuneCyte is currently in the clinical stage of developing unique chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell-based therapeutics for advanced hematopoietic cancers and solid tumors. They have also made significant progress in developing advanced cell-based gene therapies for severe cases of b-thalassemia, a devastating blood genetic disorder affecting thousands of infants annually. ImmuneCyte's commitment to innovation and their proprietary manufacturing platform make them a leader in the field of immuno-oncology.
Generated from the website